tirzepatide is glp 1 GLP-1/GIP Rx Designing a dual GLP-1R/GIPR agonist

Nutr Rev, 2006

Both versions have applications in peptide therapy, and your provider will determine which is best suited to your goals

What You Should Know Before Starting These are powerful medications, not shortcuts

Obesity prevalence among active component service members prior to and during the COVID-19 pandemic, January 2018July 2021

It is important that patients are well educated on this topic, working with doctors who understand this field and only utilize peptides made in compounding pharmacies, who understand the nuanced, delicate process of peptide production for the utmost in safety and efficacy

Following the success and approval of tirzepatide (Mounjaro, Eli Lilly, Indianapolis, IN, USA) in 2022 by FDA for treatment of T2DM, the SURMOUNT programme investigated its use as an anti-obesity medication in those without diabetes